The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: Procedures for ensuring laboratory proficiency

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 11 SUPPL. 3, 1999, Pages

  Ellard, G A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Analytical performance; Bioavailability; Rifampicin

Indexed keywords

RIFAMPICIN;

CONFERENCE PAPER; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG URINE LEVEL; HUMAN; LABORATORY TEST; PRIORITY JOURNAL;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DRUG COMBINATIONS; HUMANS; LABORATORIES; PROGRAM DEVELOPMENT; QUALITY CONTROL; RIFAMPIN; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 0032711755     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Fourie P B. Proposed minimum registration requirements for fixed-dose anti-tuberculosis combination drugs. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S362-S367.
2. Ellard G A, Fourie P B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity of ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S301-S308.
3. McIlleron H, Gabriels G, Smith P J, Fourie P B, Ellard G A. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S329-S335.
4. Brechühler S, Fluehler H, Riess W, Theobald W. The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability. Arzneim-Forsch 1978; 28: 480-483.
5. Ellard G A, Ellard D R, Allen B W, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133: 1076-1080.
6. Ellard G A, Gammon P T. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokin Biopharm 1976; 4: 83-113.
7. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tubercle Lung Dis 1995; 76: 109-113.
8. Smith P J, van Dyk J, Fredericks A. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S325-S328.
9. Panchagnula R, Sood A, Sharda N, Kaur K, Kaul C L. Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. J Pharm Biomed Anal 1999; 18: 1013-1020.
10. Dickinson J M, Aber V R, Allen B W, Ellard G A, Mitchison D A. Assay of rifampicin in serum and urine. J Clin Path 1974; 27: 457-462.
11. Panchagnula R, Kaur K J, Singh I, Kaul C L. The WHO Simplified Study Protocol in practice: investigation of combined formulations supplied by the WHO. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S336-S342.
12. Catalani E. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S289-S291.